Advertisement

Advertisement

ELCC 2018 | European Lung Cancer Congress

lung cancer

ELCC 2018: Canadian Study Shows Coordinating Nurses Can Improve Patients’ Quality of Life and Satisfaction During Lung Cancer Treatment

Investing in the continuity of care for lung cancer patients can bring tremendous benefits in terms of patient satisfaction and quality of life. In Quebec, this investment has taken the form of a dedi...

lung cancer

ELCC 2018: Second-Line Tyrosine Kinase Inhibitor Therapy Demonstrates Clinical Benefit in EGFR-Mutated NSCLC With Leptomeningeal Metastasis

Erlotinib (Tarceva) or high-dose erlotinib provides benefit in patients with epidermal growth factor receptor (EGFR) mutated non–small cell lung cancer (NSCLC) who develop leptomeningeal metasta...

lung cancer

ELCC 2018: Alectinib Provides Longer Symptom Improvement Than Crizotinib in ALK-Positive Lung Cancer

Alectinib provides longer symptom improvement than crizotinib in <em>ALK</em>-positive non–small cell lung cancer (NSCLC), according to results from the ALEX trial presented by P&eac...

Advertisement

Advertisement



Advertisement